TIDMMEDG 
 
RNS Number : 1815N 
Medgenics Inc 
07 June 2010 
 

                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
                       Statement re. Share Price Movement 
 
Medgenics (AIM: MEDG and MEDU), the company that has developed a novel 
technology for the manufacture and delivery of therapeutic proteins continuously 
in patients using their own tissue, has noted the significant share price 
movement and recent press coverage in both the MEDU and MEDG quotes. 
 
The Company confirms that it is not aware of any unpublished price sensitive 
information or of any other reason for the recent share price movements. 
 
For further information, contact: 
 
Andrew Pearlman                                              +972 4 902 8900 
CEO Medgenics, Inc 
 
Mike Wort / Anna Dunphy                                 +44 207 861 3838 
De Facto Communications (PR) 
 
James Pinner / Derek Crowhurst                        +44 207 444 0800 
Religare Capital Markets (Nomad) 
 
Ian Callaway / Alex Mattey                               +44 207 638 5600 
SVS Securities plc (Joint Broker) 
 
Jonathan Senior                                                 +44 207 776 1219 
Nomura Code (Joint Broker) 
 
 
Notes to Editors: 
About Medgenics: 
Medgenics is a commercial -stage biopharmaceutical company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The first revenue 
generating commercial deal with a well known multinational pharmaceutical 
company was negotiated in late 2009. 
Biopumps are made using needle biopsies taken from the lower layer of the 
patient's skin under local anaesthetic, and processed during 10-14 days to 
become 30 mm long tissue biofactories producing the required protein.  The 
requisite number of Biopumps are injected under the patient's skin to provide 
sustained protein production and delivery for many months. The Company is 
developing the Biopump to provide substantially greater safety and reliability 
in protein treatment in a more cost effective manner than experienced with the 
existing injected protein therapies.  Medgenics currently has three products in 
development based on this technology and addressing the indications of: 
 
 - Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Haemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effective anaemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anaemia, Hepatitis-C, and 
Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by 2010. Other potential 
applications of Biopumps producing various proteins include multiple sclerosis, 
arthritis, pediatric growth hormone deficiency, obesity, and diabetes. 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 SPMKKODKNBKDDAK
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Medgenics(Regs) Charts.